Pollution Linked to Destructive Effect on Upper Sinonasal Airway

This article originally appeared here.
Share this content:
Pollution Linked to Destructive Effect on Upper Sinonasal Airway
Pollution Linked to Destructive Effect on Upper Sinonasal Airway

WEDNESDAY, April 26, 2017 (HealthDay News) -- Exposure of the sinonasal airway barrier to chronic airborne particulate matter has destructive effects, including release of pro-inflammatory cytokines, according to an experimental study published online Feb. 28 in the American Journal of Respiratory Cell and Molecular Biology.

Murugappan Ramanathan Jr., M.D., from Johns Hopkins University in Baltimore, and colleagues subjected mice to concentrated fine particulate matter six hours per day, five days per week for 16 weeks by inhalation to examine the impact on the upper respiratory system. The mice were sacrificed and analyzed for evidence of inflammation and barrier breakdown compared with control mice.

The researchers found that there was evidence of the destructive effects of chronic airborne particulate matter on sinonasal health, including release of pro-inflammatory cytokines. Accumulation of macrophage and neutrophil inflammatory cells was seen. There was an increase in epithelial barrier dysfunction, with serum albumin accumulation in nasal airway lavage fluid, and a reduction in expression of adhesion molecules including claudin-1 and epithelial cadherin. In addition, eosinophilic inflammation increased significantly, with increased interleukin-13, eotaxin-1, and eosinophil accumulation.

"Collectively, although largely observational, these studies demonstrate the destructive effects of chronic airborne particulate matter exposure on the sinonasal airway barrier disruption and non-allergic eosinophilic inflammation in mice," the authors write.

One author holds a small amount of stock in Navigen Pharmaceuticals and is a patent co-inventor for methods treating vascular barrier dysfunction licensed to Navigen.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths